Chemed (CHE)
(Delayed Data from NYSE)
$584.89 USD
-1.28 (-0.22%)
Updated Sep 3, 2024 04:00 PM ET
After-Market: $585.47 +0.58 (0.10%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth F Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$584.89 USD
-1.28 (-0.22%)
Updated Sep 3, 2024 04:00 PM ET
After-Market: $585.47 +0.58 (0.10%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth F Momentum B VGM
Zacks News
GNC Holdings (GNC) Beats on Q1 Earnings, Plans Store Shutdown
by Zacks Equity Research
GNC Holdings (GNC) announces plans to shutter roughly 200 stores in 2018 as part of the ongoing optimization of the company's store portfolio in Q1.
Stryker (SYK) Q1 Earnings Beat Estimates, 2018 View Solid
by Zacks Equity Research
Stryker (SYK) gains from strong segmental show in Q1; a solid guidance is promising.
Varian Medical (VAR) Beats Q2 Earnings & Revenue Estimates
by Zacks Equity Research
Strong performance in the Software, Hardware and Service revenues boost Varian Medical's (VAR) Q2 results.
CONMED (CNMD) Beats on Q1 Earnings, Lifts FY18 Guidance
by Zacks Equity Research
CONMED (CNMD) gains on strong performance in core segments; raised guidance buoys optimism.
Baxter (BAX) Beats on Q1 Earnings & Revenues, Raises '18 View
by Zacks Equity Research
Solid performance in Renal Products, Medication Delivery, Pharmaceutical and Other segment boost Baxter's (BAX) Q1 results.
Zimmer Biomet (ZBH) Q1 Earnings Top Estimates, Margins Drop
by Zacks Equity Research
Zimmer Biomet (ZBH) issues full-year 2018 sales and earnings guidance in Q1.
Align Technology (ALGN) Beats on Earnings and Revenues in Q1
by Zacks Equity Research
Align Technology (ALGN) gains on solid contributions from Clear Aligner as well as Scanner and Service segments in Q1.
Chemed (CHE) Beats on Q1 Earnings & Revenues, Retains View
by Zacks Equity Research
Chemed (CHE) rides on strong contributions from the Roto-Rooter and VITAS businesses in Q1.
MedTech Stocks Q1 Earnings: Key Predictions for DGX, MD, CHE
by Zacks Equity Research
On a positive note, the broader healthcare looks delighted with the massive tax cuts. Also, the scenario within the Medical Device space seems equally bright.
Chemed (CHE) Beats on Q4 Earnings & Revenues, Issues View
by Zacks Equity Research
Chemed (CHE) rides on strong contributions from the Roto-Rooter and VITAS businesses in Q4.
Will Envision Healthcare's Growth Strategies Help the Stock?
by Zacks Equity Research
Envision Healthcare (EVHC) is expected to gain from is a number of long term growth strategies.
New Year to Bring Back MedTech Tax, 3 Stocks Unfazed
by Zacks Equity Research
Investors are apprehensive about the re-enactment of MedTech Tax and related concerns, despite raking in returns from other sectors.
4 Reasons Why Envision Healthcare (EVHC) Looks Dull
by Zacks Equity Research
Envision Healthcare continues to suffer from low patient volumes, increased leverage, high operating expense and a weak operating environment.
Zimmer Biomet Strong on Positive Data From PROGRESS II Study
by Zacks Equity Research
Zimmer Biomet (ZBH) consistently endeavors to improve its knee business.
Here's Why You Should Invest in Masimo (MASI) Right Now
by Zacks Equity Research
Masimo (MASI) rides high on its solid guidance. The company's recent FDA approval is also encouraging.
Haemonetics Banks on Hospital Business, Competition Rife
by Zacks Equity Research
For fiscal 2018, Haemonetics (HAE) expects the Hospital business to grow 7-10%.
Zacks.com highlights: Lululemon Athletica, Chemed, Baxter International, NVR and Copart
by Zacks Equity Research
Zacks.com highlights: Lululemon Athletica, Chemed, Baxter International, NVR and Copart
5 of the Best Efficient Stocks to Strengthen Your Portfolio
by Tirthankar Chakraborty
We have considered four popular ratios in order to find efficient companies that have the potential to provide impressive returns
4 Growth Stocks to Pick From a Choppy MedTech Market
by Zacks Equity Research
In the wake of the volatile political scenario and taking a few favorable metrics into account, these MedTech stocks stand out as the most suitable picks.
DaVita (DVA) Surges: Stock Moves 13.6% Higher
by Zacks Equity Research
DaVita (DVA) saw a big move last session, as its shares jumped nearly 14% on the day, amid huge volumes
Chemed Banks on Roto-Rooter Sales, Focuses on Vitas Revival
by Zacks Equity Research
Chemed (CHE) continues to display robust performance in Roto-Rooter business on strength in core plumbing and drain cleaning service segments.
Align Technology Rides High on InvisAlign & Strategic Pacts
by Zacks Equity Research
Rising demand for InvisAlign products in the global teen market and the distribution agreement with Patterson Dental are major upsides for Align (ALGN).
Zacks.com highlights: Chemed, Baxter International, IDEXX Laboratories, Advanced Energy Industries and Pioneer Natural Resources
by Zacks Equity Research
Zacks.com highlights: Chemed, Baxter International, IDEXX Laboratories, Advanced Energy Industries and Pioneer Natural Resources
5 of the Most Efficient Stocks to Boost Your Portfolio
by Tirthankar Chakraborty
Company with a favorable efficiency level generally provides impressive returns as it is believed to be positively correlated with the stock's price performance.
Envision Healthcare Down More Than 50% This Year, Here's Why
by Zacks Equity Research
Envision Healthcare (EVHC) seems to be bogged down by soft patient volumes, increasing expenses and high leverage.